Treatment of this condition with IL-17 blockade has been shown to:
A) Increase the risk of Reversible Posterior Leukoencephalopathy Syndrome
B) Worsen pre-existing multiple sclerosis
C) increase risk for mucosal candidal infections
D) Cause hepatic fibrosis with long term use
